Short Bowel Syndrome Market
Market Overview:
Short bowel syndrome is a group of problems related to poor absorption of nutrients. It can be mild, moderate, or severe, depending on how well the small intestine is functioning. The main cause of short bowel syndrome is surgery to remove a portion of the small intestine. This surgery can treat intestinal diseases, injuries, or birth defects.
Market Size Growth Rate:
The SBS market was valued at USD 1.24 billion in 2021 and is expected to reach USD 4.42 billion by 2027, and is projected to expand at a CAGR of 15.9% during the forecast period 2022-2027. Due to significant research & development, innovative medicines, extensive research, disease prevalence, and favorable reimbursement scenario are anticipated to propel the global short bowel syndrome market.
Market Drivers:
Demand for Glucagon like Peptide-2 (GLP-2) for treatment of short bowel syndrome
The GLP-2 is anticipated to be one of the leading segments of the SBS market during future growth. The only available GLP-2 analog in the market for the treatment of SBS is Gattex/Revestive. The strong growth of this segment can be attributed to the increase in prescriptions for gattex therapy, the rise in the number of patients on gattex therapy, and the high cost of the drug.
-
Gattex/Revestive is commercially available in North America and selected countries in Europe, including the U.K., Germany, France, Italy, Spain, and the Nordics.
Market Restraints:
High cost of treatment to hamper the market
-
Increasing short bowel syndrome drug prices associated with SBS treatments are currently global challenges to SBS product approaches and market outcomes. At the same time, prices differ between different countries around the world.
-
In addition, the lack of reimbursement in certain countries renders the treatment unreachable to various significant groups of people.
-
In May 2019, Gattex (teduglutide) received approval from the FDA for injection to pediatric patients 1 year of age and older with SBS. Gattex is quite expensive, with treatment costing over USD 295,000 a year
Market Opportunities:
The majority of the bleeding disorder treatment market players proactively working to develop potential therapeutic methods and drug products to improve bleeding treatment options.
-
In October 2022, Zealand Pharma received FDA approval for Orphan drug designation to Glepaglutide (long-acting GLP-2 analog) in the treatment of SBS which is currently being studied in Phase 3 clinical trials.
-
In April 2021, 9 Meters Biopharma entered into collaboration with the Duke Clinical Research Institute (DCRI) to support the clinical development of 9 Meters' candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for SBS.
-
In June 2021, VectivBio Holding AG received FDA approval for Orphan drug designation to Apraglutide, a next-generation, long-acting GLP-2 analog in rare gastrointestinal (GI) diseases, and VectivBio AG plans to initiate a phase 2 trial evaluating Apraglutide for the treatment of a GVHD in 2022.
Recent Developments in the Industry:
-
In April 2021, Hanmi Pharm. Co. Ltd. received approval from U.S.FDA for LAPS GLP-2 analog (HM15912) a new biopharmaceutical product in SBS therapy
-
On April 2020, 9 Meters Biopharma, Inc. completed the merger with RDD Pharma, Ltd., an Israel-based corporation (RDD), and changed its name from Innovate Biopharmaceuticals, Inc. to 9 Meters Biopharma, Inc.
-
In February 2020 Scottish Medicines Consortium revealed NHS Scotland approval for Revestive (teduglutide) in adult patients with SBS
Market Segmentation:
As per the research analysis, the global short bowel syndrome market is segmented by product into Glucagon-like Peptide-2 (GLP2), growth hormone, glutamine, and others by distribution channel into hospital pharmacies, retail pharmacies, and online sales
On the bases of the product, the GLP2 segment is a 33 amino acid peptide-encoded carboxyterminal to the sequence of GLP-1 in the proglucagon gene. Both GLP-1 and GLP-2 are secreted from gut endocrine cells and promote nutrient absorption through distinct mechanisms of action. It plays significant functions such as GLP-2 reduces mortality and decreases mucosal injury, cytokine expression, and bacterial septicemia in the setting of small and large bowel inflammation, and also enhances nutrient absorption and gut adaptation in humans with short bowel syndrome.
Geographical Classification:
The global short bowel syndrome market is segmented into major countries including North America, Europe, South America, Asia Pacific, and the Middle East and Africa.
North America Short Bowel Syndrome Market:
North America is the dominant region in the short bowel syndrome market and is expected to lead the market during the forecast period. The strong growth of the SBS market in this region is primarily attributed to the increase in prescriptions of Gatex therapy in the U.S. And also, the rise in the busy lifestyle that led to no time to focus on nutritious and healthy food with increased consumption of unhealthy products and junk food, resultant intestinal disorders (prevalence in the US is approximately 30 cases per million) are a major factor that drives the market growth in the region.
Europe Short Bowel Syndrome Market:
Europe also remains a favorable region due to, growing pre and post-marketing strategies of short bowel syndrome market players to enhance awareness regarding the syndrome and its treatment also contributes to the market expansion in this region. It has approximately 1.4 cases per million. In recent times, there is increasing use of anti-diarrheal, histamine blockers, and proton pump inhibitors in SBS therapeutic platforms. Moreover, the key competitive players (Zealand Pharma, Sanofi, GSK Plc., Hikma Pharmaceuticals, and others) are extensive research on syndrome activities in the market space and are expected to stimulate the demand for SBS through 2027.
Competitive Analysis:
However, it is expected to grow rapidly in the next couple of years with intense competition among the players and a rising number of cases. A few key players are already being observed adopting strategies, such as collaboration for the development of therapies and drugs, which may make the market crowded with new products in the next couple of years.
Major Companies:
Takeda Pharmaceutical Company Limited (Japan), VectivBio AG, 9 Meters Biopharma, Zealand Pharma (Denmark), Hikma Pharmaceuticals (U.K.), Johnsons & Johnsons Services Inc (U.S.), Boehringer Ingelheim International GmbH (Germany), Sun Pharmaceutical Industries Ltd. (India), Sanofi (France), GSK Plc. (U.K.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Alvogen (U.S), Merck KGaA (Germany), Swedish Orphan Biovitrum (Switzerland), OxThera, Mylan (US), AstraZeneca (UK), and Others.
What we do:
We envision a world where everybody can make the best choices based on trusted information. We are here to assist you in all your market research needs our data & intelligence services to provide in-depth knowledge about new emerging drugs, treatments & diagnostics, and insights on commercial, regulatory, technological, and clinical trial landscapes. We also help in drug pipeline analysis, product commercialization strategy, R&D planning, budgeting, and more.
About Us:
PharmaNucleus is a trusted advisor in the life science & healthcare market. Our mission is to help our clients with real-time, accurate, and reliable information from the industry.
Contact Us:
Name:
Company Address:
Contact no:
Email:
Website: http://www.pharmanucleus.com/
SOURCE PHARMA NUCLEUS